Clinical Utility of Micro RNA-148a in Egyptian Patients with Hepatocellular Carcinoma

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Shaaban M.A.A.; Elgohary E.A.; El Assaly N.M.; Hassan M.M.; Amin H.S.; Mohamed K.M.; Ibrahim I.M.; IMostafa M.; Elsawy H.W.; Kabiel W.A.

Journal: Egyptian Journal of Chemistry

Publisher: National Information and Documentation Centre

Publication Date: 19 May 2025

Volume / Issue: Volume 68 / Issue 13

Pages: 461–472

ISSN: 4492285

DOI: 10.21608/ejchem.2025.370092.11493

Scopus: View on Scopus

Document Type: Article


Authors and Affiliations

Shaaban M.A.A., Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt; Elgohary E.A., Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt; El Assaly N.M., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Hassan M.M., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Amin H.S., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Mohamed K.M., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Ibrahim I.M., Department of Tropical Medicine, Theodor Bilharz Research Institute, Egypt; IMostafa M., Department of Tropical Medicine, Theodor Bilharz Research Institute, Egypt; Elsawy H.W., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Kabiel W.A., Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt


Abstract

Hepatocellular carcinoma (HCC) is the one of the most commonly diagnosed cancersworldwide and represents one of the leading causes of cancer-related death. HCC is associated with bad prognosis, as most patients present with advanced stages at the time of detection. Aberrant expression of miRNA-148a is found in HCC.This motivatesresearchersto evaluate miR-148a in HCC.The aim of our study was to assess the clinical utility of miR-148a as a non-invasive marker for early detection of HCC in addition to its prognostic value. This study was conducted on 64 subjects, undertitled into three groups: HCC, hepatitis C virus (HCV) and control groups. miR-148a was analyzed in serum by quantitative real time polymerase chain reaction (qRT-PCR). Results showed that miR-148a expression revealed a significant difference between groups with the HCC group revealing the lowest values. The HCC group revealed a negative correlation between miR-148a and primary tumor, tumor size, TNM staging andalpha-fetoprotein(AFP). Receiver operator characteristics (ROC) curve was constructed to estimate discrimination of HCC group versus the other groups through serum biomarker miR-148a and AFP. The best cut-off for miR-148a was ≤ 7.331 (2–ΔΔCT), with sensitivity 82.4 % and specificity 80 %. As for AFP, the best cut-off level was 25 ng/mL with sensitivity 70.6% and specificity 63.3%.As a conclusion, miR-148a was found to be downregulated in Egyptian patients with HCC. Our findings thus propose that miRNA-148a can be beneficial for early diagnosis of HCC, as well as having a prognostic value. © 2025 National Information and Documentation Center (NIDOC)


Keywords

hepatocellular carcinoma; microRNA; microRNA-148a


Citation Information

Scopus Citations: 1


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region